Myerson R J, Michalski J M, King M L, Birnbaum E, Fleshman J, Fry R, Kodner I, Lacey D, Lockett M A
Radiation Oncology Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):41-50. doi: 10.1016/0360-3016(94)00493-5.
To review predictors of outcome, including sequencing of modalities and pretreatment findings for adjuvantly treated rectal cancer.
From 1975 through 1990, 307 patients with adenocarcinoma of the rectum underwent adjuvant radiation therapy. In 251 cases the radiation therapy was administered preoperatively, either 40-50 Gy (median dose 45 Gy) followed in 6-7 weeks by surgery (210 cases), or 20 Gy in five fractions immediately prior to surgery (41 cases). In 56 cases, patients were referred postoperatively for radiation (median dose 50 Gy). Adjuvant chemotherapy was never given concurrently with the preoperative radiation (RT), although 43 of the cases (including 14 of the preoperative RT cases) received postoperative chemotherapy.
Multivariate analysis (Cox model) indicated that significant predictors of better overall freedom from disease were preoperative rather than postoperative RT (p < 0.001), low surgical stage (p < 0.0001), specialist surgeon (p = 0.007), low or moderate histologic grade (p = 0.026), and proximal lesion (p = 0.033). The significant predictors for better local control included use of preoperative RT (p < 0.001), low or moderate grade (p = 0.001), and low surgical stage (p = 0.015). The 5-year local control and freedom from disease for the preoperative RT patients were 90% +/- 2% and 73% +/- 3%, respectively. The selected cases that received the short course of 20 Gy preoperatively did well. Although 24 out of 41 patients proved to have Astler Coller B2 or C disease, local control at last follow-up was 39 out of 41 (95%). A second multivariate analysis of pretreatment factors was performed on the preoperative RT cases. The significant factors for both local control and overall freedom from disease were noncircumferential vs. circumferential tumor, proximal vs. distal lesion, and background of the surgeon. Additional negative factors on univariate analysis (although not achieving independent significance on multivariate analysis) included the finding of near-obstructing lesions and elevated carcinoembryonic antigen (CEA). Grade > or = 3 sequelae occurred in 8% of cases (including 3% bowel obstruction). The only significant factor for complications was background of the surgeon (4% for colorectal specialists vs. 12% for nonspecialists, p = 0.015).
Significant factors for better tumor control included preoperative as opposed to postoperative RT and the experience of the surgeon. In selected cases, excellent results can be obtained with a short course of preoperative radiation. Concurrent chemotherapy need not be given routinely with preoperative radiation. Subgroups of preoperative RT cases at risk for distant metastases (who might benefit from postoperative chemotherapy), and at high risk for local failure (for whom concurrent preoperative chemotherapy and radiation might be considered), are identified.
回顾辅助治疗直肠癌的预后预测因素,包括治疗方式的顺序及治疗前的检查结果。
1975年至1990年间,307例直肠腺癌患者接受了辅助放射治疗。251例患者在术前接受放射治疗,其中210例接受40 - 50Gy(中位剂量45Gy)照射,6 - 7周后进行手术;41例在手术前即刻接受5次分割共20Gy照射。56例患者在术后接受放射治疗(中位剂量50Gy)。术前放射治疗(RT)期间从未同时给予辅助化疗,不过43例患者(包括14例术前RT患者)接受了术后化疗。
多因素分析(Cox模型)表明,总体无病生存期较好的显著预测因素为术前而非术后放疗(p < 0.001)、低手术分期(p < 0.0001)、专科外科医生(p = 0.007)、低或中等组织学分级(p = 0.026)以及肿瘤近端病变(p = 0.033)。局部控制较好的显著预测因素包括术前放疗的应用(p < 0.001)、低或中等分级(p = 0.001)以及低手术分期(p = 0.015)。术前RT患者的5年局部控制率和无病生存率分别为90%±2%和73%±3%。术前接受20Gy短程放疗的选定病例效果良好。尽管41例患者中有24例被证实为Astler Coller B2或C期疾病,但最后一次随访时41例中有39例(95%)实现了局部控制。对术前RT病例的治疗前因素进行了第二次多因素分析。局部控制和总体无病生存的显著因素为肿瘤非环周与环周、近端与远端病变以及外科医生的背景。单因素分析中的其他负面因素(尽管在多因素分析中未达到独立显著性)包括发现接近梗阻性病变和癌胚抗原(CEA)升高。8%的病例出现≥3级后遗症(包括肠梗阻3%)。并发症的唯一显著因素是外科医生的背景(结直肠专科医生为4%,非专科医生为12%,p = 0.015)。
更好的肿瘤控制的显著因素包括术前而非术后放疗以及外科医生的经验。在选定病例中,术前短程放疗可取得优异结果。术前放疗无需常规同时给予化疗。确定了术前RT病例中存在远处转移风险(可能从术后化疗中获益)以及局部失败高风险(可考虑术前同步化疗和放疗)的亚组。